Dr. Kuter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Yaw 7b Hematology Oncology
Boston, MA 02114Phone+1 617-724-6193Fax+1 617-643-1915
Education & Training
Massachusetts General HospitalResidency, Internal Medicine, 1978 - 1983
Harvard Medical SchoolClass of 1978
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology
Certifications & Licensure
MA State Medical License 1987 - 2025
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures Start of enrollment: 2006 Mar 01
- Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study) Start of enrollment: 2008 Jan 01
- Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2009 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label e...Nichola Cooper, James B Bussel, Maciej Kaźmierczak, Yoshitaka Miyakawa, Sarah Cluck
British Journal of Haematology. 2024-11-18 - Cognitive impairment among patients with chronic immune thrombocytopenia.David J Kuter, Umer Khan, Paul Maruff, Ahmed Daak
British Journal of Haematology. 2024-07-01 - 1 citationsCorrection to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patientreported outcomes from the CARDINAL study.Alexander Röth, Wilma Barcellini, Tor Henrik Anderson Tvedt, Yoshitaka Miyakawa, David J Kuter
Annals of Hematology. 2024-05-01
Journal Articles
- Romiplostim in Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia (ITP) for up to 1 Year and in Those with Chronic ITP for More Than 1 Year: A S...David J Kuter, Bhakti Mehta, British Journal of Haematology
- Presenting Signs and Patient Co‐Variables in Gaucher Disease: Outcome of the Gaucher Early Diagnosis Consensus (GED‐C) Delphi InitiativeDavid J Kuter, Neal J Weinreb, Internal Medicine Journal
Abstracts/Posters
- Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune ThrombocytopeniaDavid J. Kuter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 StudiesAmerican Thoracic Society, 2013 International Conference, Philadelphia, Pennsylvania, USA
- Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies2013 International Conference, Philadelphia, Pennsylvania, USA
- Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Other
- Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based ConsiderationsDavid Kuter, MD, Haematologica
https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
UpToDate, Wolters Kluwer Health - 2012-07-24 - Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based ConsiderationsDavid Kuter, MD, Haematologica
https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
UpToDate, Wolters Kluwer Health - 2013-01-30 - Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 StudiesDavid Kuter, MD, British Journal of Haematology
https://www.doximity.com/articles/d909d298-5043-4c91-b3f6-84a999dd1fef
UpToDate, Wolters Kluwer Health - 2012-09-07
Press Mentions
Rilzabrutinib Found Safe and Effective for Refractory Immune ThrombocytopeniaDecember 13th, 2024- Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune ThrombocytopeniaDecember 8th, 2024
- Press Release: ASH: Rilzabrutinib Demonstrated Significant Patient Benefit in the First Positive Phase 3 Study of a BTK Inhibitor in ITPDecember 7th, 2024
- Join now to see all
Grant Support
- MGH Transfusion Medicine And Hemostasis Network Clinical Core CenterNational Heart, Lung, And Blood Institute2009
- A Proteogenomic Analysis Of Platelets In Patients With Essential ThrombocythemiaNational Heart, Lung, And Blood Institute2007–2008
- A Proteogenomic Analysis Of Platelets In Patients With *National Heart, Lung, And Blood Institute2006
- Studies Of Rhutpo In ITP And Of Rvlla In Liver DiseaseNational Heart, Lung, And Blood Institute2002–2006
- Proteogenomic Analysis Of Platelets In ThrombocythemiaNational Heart, Lung, And Blood Institute2005
- Molecular And Cellular Mechanisms Of Platelet ViabilityNational Heart, Lung, And Blood Institute1998–2001
- Molecular Physiology Of ThrombopoietinNational Heart, Lung, And Blood Institute1995–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
